Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis

Gastroenterology

Volumn 121, Issue 1, 2001, Pages 148-155

  Jonsson, Julie R ^a   Clouston, Andrew D ^a   Ando, Yuichi ^a   Kelemen, Livia I ^a   Horn, Murray J ^a   Adamson, Michael D ^a   Purdie, David M ^a   Powell, Elizabeth E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE A; GELATINASE B; MESSENGER RNA; PROCOLLAGEN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; GENOTYPE; HEART MUSCLE FIBROSIS; HEPATITIS C; INHERITANCE; KIDNEY FIBROSIS; LIVER DISEASE; LIVER FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STEADY STATE;

EID: 0034961836     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2001.25480     Document Type: Article

References (37)

1. Cytokines and fibrogenesis
2. Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats
3. Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney
4. Host genetic factors influence disease progression in chronic hepatitis C
5. The effect of captopril treatment and its withdrawal on the gene expression of the renin-angiotensin system
6. Classification of chronic viral hepatitis: A need for reassessment
7. Hepatic stellate cell activation in genetic haemochromatosis. Lobular distribution, effect of increasing hepatic iron and response to phlebotomy
8. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues
9. Schistosoma mansoni: Relationship of tumor necrosis factor-alpha to morbidity and collagen deposition in chronic experimental infection
10. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
11. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis
12. Molecular insights into angiotensin II type 1 and type 2 receptors: Expression, signaling and physiological function and clinical application of its antagonists
13. Angiotensin II induces contraction and proliferation of human hepatic stellate cells
14. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril
15. Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney
16. Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis. Alpha-smooth muscle actin is a marker of mesangial cell proliferation
17. Phenotypic modulation of alveolar myofibroblasts in transplanted human lungs
18. Angiotensin II in renal fibrosis: Should TGF-β rather than blood pressure be the therapeutic target?
19. Stimulation of autocrine platelet-derived growth factor AA-homodimer and transforming growth factor β in vascular smooth muscle cells
20. Vascular smooth muscle cell hypertrophy vs hyperplasia: Autocrine transforming growth factor-β1 expression determines growth responses to angiotensin II
21. Antagonism of the renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes
22. Dual expression of matrix metalloproteinase-2 and membrane-type 1: Matrix metalloproteinase in fibrotic human livers
23. Fibrosis and altered matrix degradation
24. Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases
25. Mitochondrial membrane perturbations in cholestasis
26. Different effects of thiol and nonthiol ACE inhibitors on copper-induced lipid and protein oxidative modification
27. Captopril reduces collagen and mast cell and eosinophil accumulation in pig serum induced rat liver fibrosis
28. Current pharmacotherapeutic strategies in the treatment of arterial hypertension
29. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors
30. Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing
31. Alpha-interferon prevents liver collagen deposition and damage induced by prolonged bile duct obstruction in the rat
32. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats
33. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial of interferon nonresponders
34. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis
35. Inhibition of hepatic fibrogenesis: A review of pharmacologic candidates
36. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology